Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose therapy for relapsed or refractory aggressive non-Hodgkin lymphoma
ISRCTN09311427Phase 2Completed
- Sponsor
- East German Study Group on Hematology and Oncology
- Start
- Aug 2004
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of rituximab, dexamethasone, cytarabine and cisplatin in non-Hodgkin lymphoma (NHL) (2 arms), sponsored by East German Study Group on Hematology and Oncology. Primary endpoints: Toxicity of the regimen, Overall survival and 1 more. Started Aug 2004; status: completed.
02
Drugs
rituximabdexamethasonecytarabinecisplatin
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on ISRCTN09311427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN09311427.